# To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

> **NCT06647550** · PHASE2 · RECRUITING · sponsor: **Hyundai Pharm** · enrollment: 160 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** HD-6277 100mg
- **DRUG:** HD-6277 50mg
- **DRUG:** HD-6277 25mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06647550
- **Lead sponsor:** Hyundai Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647550, "To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06647550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*